The prevalence of duplicate participants in clinical trials poses significant risks, compromising the integrity of data and the safety of the patients involved. To delve into this matter, we spoke with Kerri Weingard, a seasoned veteran in the field and the co-founder of Verified Clinical Trials (VCT), who brings a wealth of knowledge and experience. In this …
January 30, 2025 07:07 ET | Source: Velocity Clinical Research, Inc.Follow DURHAM, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) — Velocity Clinical Research, the leading multi-specialty clinical research organization, has partnered with Verified Clinical Trials (VCT) to set a new benchmark for patient safety and data quality in clinical trials through a new technological implementation at Velocity’s 80+ …
In the dynamic world of clinical research, ensuring data integrity and participant safety is paramount. One of the most significant challenges faced by clinical trials today is the issue of duplicate subjects in clinical trials—participants who enroll in multiple studies simultaneously or consecutively without proper washout periods. This practice can jeopardize study outcomes, compromise data …
We’re excited to announce that Verified Clinical Trials (VCT) will be exhibiting and hosting a special panel discussion focused on the growing challenges of duplicate and professional subjects in vaccine clinical trials. Vaccine clinical trials present a unique set of challenges, particularly when it comes to subject verification. Unlike many other clinical studies, vaccine trials …
Vaccine clinical trials pose unique challenges with regards to duplicate research subjects or professional subjects. Typically, large numbers of subjects are dosed at the first visit in a vaccine clinical trial. There is no way for a site or principal investigator to adequately check if the research subject is a duplicate or professional subject. Subjects …
There are many obstacles to the success of a clinical trial and duplicate research subjects, or professional research subjects are unfortunately one of them. Duplicate subjects in clinical trials results in a myriad of poor outcomes. Ultimately duplicate research subjects can result in a clinical trial failing to meet its endpoints. And now with decentralized …
Clinical research patients are compensated for their participation in clinical trials. In some therapeutic areas and types of clinical trials, the compensation for enrolling in one or more clinical trials or at multiple research sites is enough to influence patients to join more than one contemporaneously and expose themselves to multiple investigational products or multiple …
Duplicate subjects, or what is known as professional research subjects, exist in most clinical trials to varying degrees. CNS clinical trials are especially prone to duplicate subjects or over enrollment in clinical tials. The issue exists from phase 1 healthy volunteer studies to multiple phase 2/3 clinical trials across many therapeutic indications. Use of global …
Professional research subjects cause issues with placebo rates, data quality and safety. The issue is more common than most would think. Upwards of 10% of research subjects will attempt to enroll in more than one clinical trial concurrently or before a safe and mandatory wash out period has occurred. Without a tool like Verified Clinical …
We have seen tremendous progress within the clinical trials research industry in understanding the scope of the issue with duplicate subjects in clinical trials or professional research subjects over the past few years. Verified Clinical Trials (VCT) provides an easy to implement cost-savings approach to prevent duplicate subjects and other important protocol violations in your …
